Pancreatic cancer: SELENBP1 is downregulated in pancreatic ductal adenocarcinoma (PDAC) patients with skin rash (SR) treated with erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (Caba et al., 2016). Here, EGFR is linked to exanthem.